Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cilomilast · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| cilomilast | DRUG | - |
Inclusion criteria: * Diagnosis of COPD and a history of cigarette smoking. Exclusion criteria: * Significant heart or lung disease not associated with COPD. * Significant stomach or intestinal disease.
Cilomilast is an investigational small molecule being developed for the treatment of chronic obstructive pulmonary disease (COPD). It is intended for patients with this respiratory condition, which involves airflow obstruction and breathing difficulties. The drug is currently in Phase 3 clinical development, meaning it has not yet been approved for use.
Cilomilast is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with chronic obstructive pulmonary disease.
Cilomilast is in Phase 3 clinical development. This is the final stage of testing before a potential regulatory submission. The drug is being studied for chronic obstructive pulmonary disease, and it remains investigational, meaning it is not yet approved by regulatory authorities.
Cilomilast has one completed Phase 3 clinical trial with the identifier NCT00103922. This study enrolled 600 participants with chronic obstructive pulmonary disease in the United States. The trial was randomized and double-blind, and it has been completed, with no active trials currently ongoing.
Cilomilast is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for chronic obstructive pulmonary disease. The drug has completed a Phase 3 trial, but it has not yet received approval from the FDA or other regulatory agencies.